| Code | CSB-RA004935MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Semzuvolimab, targeting the CD4 glycoprotein expressed on T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. CD4 serves as a critical co-receptor for T cell receptor (TCR)-mediated activation and is essential for adaptive immune responses. As the primary receptor for HIV-1 entry, CD4 plays a central role in viral pathogenesis and immune dysfunction. Additionally, CD4-expressing cells are implicated in autoimmune disorders, transplant rejection, inflammatory diseases, and various malignancies including T cell lymphomas and leukemias.
Semzuvolimab is a murine IgG1κ monoclonal antibody that targets the CD4. It binds to CD4, which interferes with the binding of the HIV viral envelope protein gp120 to the CD4 receptor, thereby preventing the virus from entering the cell. It has undergone clinical research to explore its use in the treatment of HIV infection, including the effect of inhibiting HIV in patients who are stably receiving highly active antiretroviral therapy (HAART). This biosimilar provides researchers with a valuable tool for investigating CD4 biology, T cell signaling pathways, immune cell interactions, and disease mechanisms. It supports studies exploring immune regulation, host-pathogen interactions, and the development of immunomodulatory strategies. The antibody enables detailed characterization of CD4-dependent processes in both normal physiology and pathological states.
There are currently no reviews for this product.